Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #98 on AstraZeneca PLC (AZN)
biotech_researcher
12/01/17 4:18 PM
#115 RE: north40000 #98
Several AZN-based tweets from attendees at the SGO convention[in suburban Washington, D.C.] the past few days suggested that there is a need for an early detection and diagnostic means for ovarian cancer...patients in later stages of ovarian cancer have not survived well, if at all: insider.foxnews.com/2017/02/03/robert-kraft-donald-trump-friendship-super-bowl The content of the following links suggests there is a proof-of-concept solution to that problem, from researchers at UTSW, that is not yet widely known---it is based on "exosome" technology: http://www.exosome-rna.com/proof-of-concept-data-for-a-novel-exosome-based-cancer-detection-platform-published/ See the Abstract, Introduction, and description[note the reference to 100% accuracy in ability to distinguish active tumor cells from benign cells from normal cells present in a blood sample] accompanying fig.4 of the above referenced article set forth here: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=14795&path%5B%5D=47251 All cancers might be detected and diagnosed using the blood sampling means/technique described above, according to the UTSW researchers: http://www.utsouthwestern.edu/edumedia/edufiles/about_us/admin_offices/technology_development/available_technologies/utsd-2932.pdf See particularly Table 1 and Examples 6-8 of the authors' published patent application: http://tinyurl.com/gqvwkga Previously, I had sent[February 2017] the gist of the above to 1) the Bidens at their foundation, 2)Joy Drake at OCRFA.org, for distribution to colleagues at the Ovarian Cancer Research Fund Alliance, 3) Dr.Jon LaPook at CBS news, 4) contacts I have at BMGF, 5) Dr. Jedd Wolchok at MSKCC and a few others. I interspersed my comments as appropriate to each of above. I have met and talked with Dr. Wolchok previously at his Wistar lecture in Philadelphia in early December 2016. My purposes: to try to create publicity, and perhaps funding, to bring the proof-of-concept research of Dr. Schroit et al at UTSW 1) to any fruition, and 2) to the attention of members of the public that might be interested. I have no idea whether/if/when those purposes have been, or will be, fulfilled.